Financial Architects, Inc Prothena Corp Public LTD CO Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $59 - $136	-8 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$10.32 - $14.49 $82 - $115	8 New	8 $0
Q1 2019 May 03, 2019	SELL	$10.32 - $14.49 $82 - $115	-8 Closed	0 $0
Q2 2018 Aug 03, 2018	BUY	$10.99 - $44.21 $87 - $353	8 New	8 $0
Q1 2018 Apr 23, 2018	SELL	$27.95 - $45.04 $27 - $45	-1 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$35.44 - $63.76 $35 - $63	1	1 $0

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $708M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.